2100 Abbot Kinney Blvd.
5 articles with Seed Health
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
New Series A financing rounds have been announced in the last two days, with Seed Health leading the pack followed by Anavo Therapeutics.
Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research
Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, announced the close of a $40 million Series A financing led by impact investor, The Craftory, alongside TechBio investor ARTIS Ventures and life science investor GISEV, with participation from existing investors, Founders Fund and 8VC.
Seed Health, a microbial sciences company, announced the acquisition of Auggi, a digital health company with a suite of artificial intelligence and machine learning technologies to track and analyze digestive health.
FDA authorizes new IND to evaluate impact of multi-strain probiotic DS-01™ on gut microbiota of patients with IBS
Seed Health, a microbial sciences company, today announced U.S. Food and Drug Administration (FDA) authorization of its Investigational New Drug (IND) application for DS-01™, a broad spectrum multi-species, multi-strain probiotic.